Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Shahid Beheshti University of Medical Sciences.
Recruitment status was  Recruiting
Information provided by:
Shahid Beheshti University of Medical Sciences Identifier:
First received: August 30, 2006
Last updated: November 13, 2006
Last verified: November 2006
To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.

Condition Intervention Phase
Neovascular Age-Related Macular Degeneration
Drug: verteporfin, bevacizumab, triamcinolone acetonide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti University of Medical Sciences:

Primary Outcome Measures:
  • Visual acuity

Secondary Outcome Measures:
  • Central macular thickness
  • Leakage in fluorescein angiography
  • Intraocular pressure
  • Anterior chamber reaction

Study Start Date: September 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria:

  • History of glaucoma or ocular hypertension
  • Disciform scar
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00370539

Contact: Hamid Ahmadieh, MD +98 21 22585952

Iran, Islamic Republic of
Hamid Ahmadieh, MD Recruiting
Tehran, Iran, Islamic Republic of, 16666
Contact: Hamid Ahmadieh, MD    +98 21 22585952   
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
  More Information Identifier: NCT00370539     History of Changes
Other Study ID Numbers: 8542 
Study First Received: August 30, 2006
Last Updated: November 13, 2006
Health Authority: Iran: Ethics Committee

Keywords provided by Shahid Beheshti University of Medical Sciences:
Photodynamic therapy,
Age-related macular degeneration,
Choroidal neovascular membrane

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Triamcinolone hexacetonide
Triamcinolone Acetonide
Triamcinolone diacetate
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Photosensitizing Agents
Dermatologic Agents processed this record on October 27, 2016